avapritinib
blueprint medicines,illumina
['pathfinder', 'grail']
schrag #aacr23 mced in pathfinder (using grail's methylated cfdna assay). goals: dx evaluations by a 'signal received'. pt / physician to find diagnostic resolution. 12 mo follow-up. &gt;50 yo, high risk cohort - smoker, family history. majority women. 92 / 6529 or 1.4%.
Business development, marketing and sales professional in the life sciences, cancer diagnostics, and genomics fields. Blog: https://t.co/IeMzCogxlt. Opinions are my own.